Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/25/2025

Management of Febrile Neutropenia After Chemotherapy

Initial Assessment and Risk Stratification

  • The American Society of Clinical Oncology recommends initiating broad-spectrum intravenous antibiotics with antipseudomonal activity immediately upon diagnosis of febrile neutropenia, defined as fever >38.5°C with absolute neutrophil count <0.5 × 10⁹/L 1, 2
  • Obtain blood cultures from peripheral sites and all lumens of central venous catheters before antibiotic administration, as recommended by the Infectious Diseases Society of America 1
  • Document vital signs including temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation, according to the American College of Physicians 1
  • Assess for infection sources, such as skin, oral cavity, lungs, abdomen, and perianal area, as suggested by the National Comprehensive Cancer Network 1
  • Order baseline laboratory tests, including complete blood count with differential, renal function, liver function, and C-reactive protein, as recommended by the European Society for Medical Oncology 1
  • Calculate MASCC risk score to stratify patients, with scores >21 indicating low risk and scores <15 indicating high risk, according to the Multinational Association for Supportive Care in Cancer 1, 2

Immediate Empiric Antibiotic Therapy

  • The Infectious Diseases Society of America recommends starting broad-spectrum monotherapy with an antipseudomonal beta-lactam agent immediately, such as cefepime 2g IV every 8 hours or piperacillin-tazobactam 4.5g IV every 6 hours 1, 3
  • Add vancomycin or teicoplanin if hemodynamic instability or septic shock is present, or if suspected catheter-related infection, skin or soft tissue infection, or known colonization with MRSA, as recommended by the American Society of Health-System Pharmacists 3, 1, 4

Antifungal Therapy

  • The European Society for Clinical Microbiology and Infectious Diseases recommends starting antifungal therapy if persistent fever after 4-6 days of appropriate antibacterial therapy, or if high-risk patients have acute leukemia, allogeneic stem cell transplant, or prolonged neutropenia >7 days 3, 7, 4
  • Use voriconazole or liposomal amphotericin B as first-line antifungal agents for suspected invasive aspergillosis or mold infection, as recommended by the Infectious Diseases Society of America 5, 4

Duration of Antibiotic Therapy

  • The American College of Physicians recommends discontinuing antibiotics if the patient has been afebrile for 48 hours, has no symptoms of active infection, and has negative blood cultures, in patients with neutrophil count ≥0.5 × 10⁹/L 3, 7, 6
  • Discontinue antibiotics if the patient has been afebrile for 5-7 days, has no complications, and has neutrophil count <0.5 × 10⁹/L, as recommended by the National Comprehensive Cancer Network 3, 7, 6

Monitoring and Follow-Up

  • The European Society for Medical Oncology recommends assessing clinical status every 2-4 hours if critically ill, otherwise daily, and monitoring fever trends and vital signs daily 3, 7
  • Check complete blood count daily until neutrophil recovery, and monitor renal function daily, as recommended by the American Society of Clinical Oncology 3, 7